Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Notes Payables (2023 - 2025)

Perspective Therapeutics' Notes Payables history spans 3 years, with the latest figure at $55000.0 for Q3 2025.

  • For Q3 2025, Notes Payables rose 7.84% year-over-year to $55000.0; the TTM value through Sep 2025 reached $55000.0, up 7.84%, while the annual FY2024 figure was $52000.0, 6.12% up from the prior year.
  • Notes Payables for Q3 2025 was $55000.0 at Perspective Therapeutics, up from $54000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $80000.0 in Q1 2023 and bottomed at $48000.0 in Q3 2023.
  • The 3-year median for Notes Payables is $53000.0 (2025), against an average of $56090.9.
  • The largest annual shift saw Notes Payables crashed 37.5% in 2024 before it grew 7.84% in 2025.
  • A 3-year view of Notes Payables shows it stood at $49000.0 in 2023, then increased by 6.12% to $52000.0 in 2024, then rose by 5.77% to $55000.0 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Notes Payables are $55000.0 (Q3 2025), $54000.0 (Q2 2025), and $53000.0 (Q1 2025).